Leo Foundation's new CIO looks forward to life without MIFID II

At the start of October, a top member of Danske Capital's team swapped his job at the Danish banking group for the foundation that owns Danish drugmaker Leo Pharma. The limits of MIFID II are now a thing of the past, says Morten Stampe Christensen.

Morten Stampe Christensen, new CIO at Leo Foundation. | Photo: LEO Foundation

So far, there will be nine people at the office party this Christmas at Morten Stampe's new workplace, Leo Foundation, best known for owning the Danish drug company Leo Pharma A/S.

Morten Stampe Christensen came from a position as Senior Vice President and Head of Asset Allocation and Macro at Danske Capital, but now he has turned his working life upside-down with his new job as of Oct. 1 this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Velliv dives into fintech venture

Collaboration with Upfin, the first venture fund dedicated to targeting Danish fintech companies, will give Velliv access to fintech investments also in the Nordics.

Oil services investments and inflows help BankInvest in Q1

Net inflows have exceeded expectations at BankInvest in Q1. The EUR 20bn manager has been criticized for some of the investments in its sustainable flagship product, but CEO Lars Bo Bertram is proud that the EUR 12bn fund has managed to beat its benchmark despite massive gains for oil and gas.

Further reading

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch